StockData
Kura Oncology, Inc. logo

Kura Oncology, Inc. (KURA) stock

KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$7.34−0.15 (-2.00%)

Close on Nov 18, 2026Market cap $652.97MP/E –Yield –

Kura Oncology profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Kura Oncology's profit margin for the twelve months ending Sep 30, 2026 was -369.3%. For fiscal 2025 it was -412.9%, against -322.9% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-412.9%−90.1
FY2024Dec 31, 2024-322.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-307.4%+49.8
Q2 FY2026Jun 30, 2026-327.3%+105.2
Q1 FY2026Mar 31, 2026-401.5%+5.6
Q4 FY2025Dec 31, 2025-467.2%–
Q3 FY2025Sep 30, 2025-357.2%–
Q2 FY2025Jun 30, 2025-432.5%–
Q1 FY2025Mar 31, 2025-407.1%–

More Kura Oncology figures

See a number that looks wrong?